Products
Tobevibart Biosimilar Monoclonal Antibody for Research
Cat No.: GMP-Bios-INN-1422
Anti-Human Papillomavirus Envelope Protein therapeutic antibody (Pre-made Tobevibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tobevibart (development codes VIR-3434/BRII-877) is a monoclonal antibody targeting hepatitis B virus surface envelope protein (HBsAg). It is developed by Vir Biotechnology for Hepatitis B, Hepatitis D in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1422-1mg | 1mg | 3090 |
| GMP-Bios-INN-1422-10mg | 10mg | |
| GMP-Bios-INN-1422-100mg | 100mg | |
| GMP-Bios-INN-1422-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tobevibart biosimilar, Whole mAb: Anti-Human Papillomavirus Envelope Protein therapeutic antibody |
| INN Name | Tobevibart |
| Target | Human Papillomavirus Envelope Protein |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Vir Biotechnology |
| Conditions Approved | na |
| Conditions Active | Hepatitis B;Hepatitis D |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
